Mitomycin C (Synonyms: 丝裂霉素 C ; Ametycine)

目录号: HY-13316 纯度: 99.98%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Mitomycin C (Ametycine) 是一种 DNA 交联剂 (DNA cross-linking agent)，诱导 DNA 损伤。Mitomycin C 是一种抗肿瘤化合物和抗生素，可有效的抑制 DNA 合成 (DNA synthesis)。Mitomycin C 是一种 ADC 毒性分子 (ADC Cytotoxin)，可以诱导凋亡 (Apoptosis) 作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mitomycin C Chemical Structure

CAS No. : 50-07-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥493	In-stock
10 mg	￥780	In-stock
50 mg	￥2000	In-stock
100 mg	￥3000	In-stock
200 mg	￥4850	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 113 篇科研文献

Proliferation Assay

: Mitomycin C purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 30;7(1):4469. [Abstract]; In order to normalize the potential effect of cell proliferation, Mitomycin C is added to the culture media to make the cells uniformly arrested. The results show that all migration cell indexes reduced after adding Mitomycin C than those observed without Mitomycin C. Knockdown of RAD51-AS1 still inhibits cell migration (A) and invasion of SKOV3, SKOV3.ip and HO8910 cells (B), while overexpression of RAD51-AS1 only increased cell invasion capacity of the OVCAR3 cells, not in the Hey cells (C).

: Mitomycin C purchased from MCE. Usage Cited in: Exp Cell Res. 2016 Feb 15;341(2):157-65. [Abstract]; Curcumin inhibits the migration of BCPAP cells. Migration of cancer cells is assayed by wound-healing assay. Cells are cultured to nearly confluent cell monolayer and pretreated with Mitomycin C (10 μg/mL) for 2 h, followed by either DMSO or different dosages of curcumin for 6 h, before cells are wounded using yellow pipette tips. The cells are washed with PBS, and cultured for additional 24 h at 37 °C. (A) Photographs are taken after wound initially made and healing for 24 h. Data are represent

Mitomycin C 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

查看所有亚型

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Mitomycin C (Ametycine) is a DNA cross-linking agent and induces DNA damaging. Mitomycin C is an antitumor agent and antibiotic that shows extraordinary ability to inhibit DNA synthesis. Mitomycin C is an ADC Cytotoxin and induces apoptosis^[1]^[2]^[3].

IC₅₀ & Target

Traditional Cytotoxic Agents

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	GI₅₀	0.21 μM Compound: Mitomycin	Growth inhibition of human 786-O cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human 786-O cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
A2780	IC₅₀	0.18 μM Compound: MMC; MCC	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33581556]
A549	IC₅₀	0.04 μM Compound: Mitomycin-C	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25259515]
A549	GI₅₀	0.08 μM Compound: Mitomycin	Growth inhibition of human A549 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human A549 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
A549	IC₅₀	0.24 μM Compound: MMC, mitomycin c	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 18037301]
A549	IC₅₀	0.27 μM Compound: Mitomycin	Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 31490685]
A549	IC₅₀	0.3 μM Compound: Mitomycin C	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 16038545]
A549	IC₅₀	0.4 μM Compound: MMC	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 23123017]
A549	IC₅₀	0.4 μM Compound: mitomycin C	Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay	[PMID: 18752870]
A549	IC₅₀	0.4 μM Compound: MMC, mitomycin c	Cytotoxicity against human A549 cells by Alamar blue assay Cytotoxicity against human A549 cells by Alamar blue assay	[PMID: 18037301]
A549	IC₅₀	0.4 μM Compound: Mitomycin-C	Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay	10.1007/s00044-012-0424-0
A549	IC₅₀	0.4 μM Compound: Mitomycin-C	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay	10.1039/C3MD00055A
A549	EC₅₀	0.43 μM Compound: mitomycin	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
A549	EC₅₀	0.43 μM Compound: Mitomycin	Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method	[PMID: 17950604]
A549	IC₅₀	0.45 μM Compound: Mitomycin C	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay	[PMID: 25442306]
A549	IC₅₀	0.54 μg/mL Compound: Mitomycin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
A549	IC₅₀	0.63 μM Compound: MMC; MCC	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33581556]
A549	IC₅₀	1.7 μM Compound: Mitomycin	Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 26615890]
A549	IC₅₀	11.03 μM Compound: Mitomycin C	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
A549	IC₅₀	15.525 μM Compound: 1	Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay	[PMID: 28395199]
A549	IC₅₀	2.75 μM Compound: Mitomycin C	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
A549	IC₅₀	3 μM Compound: mitomycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22545792]
A549	IC₅₀	4.5 μM Compound: MMC, mitomycin c	Cytotoxicity against human A549 cells after 24 hrs Cytotoxicity against human A549 cells after 24 hrs	[PMID: 18037301]
A549	EC₅₀	5.2 μM Compound: MMC	Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay	[PMID: 26508550]
Bcap37	IC₅₀	2.33 μg/mL Compound: Mitomycin	Antitumor activity against human Bcap37 cell line by MTT assay Antitumor activity against human Bcap37 cell line by MTT assay	[PMID: 16455245]
BeWo	IC₅₀	0.06 μM Compound: Mitomycin	Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27010926]
BeWo	IC₅₀	0.85 μg/mL Compound: (21) mitomycin	In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
BXPC-3	GI₅₀	0.38 μM Compound: Mitomycin	Growth inhibition of human BxPC3 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human BxPC3 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
Caco-2	IC₅₀	5.8 μM Compound: Mitomycin	Cytotoxicity against human Caco2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 31490685]
Ca-Ski	IC₅₀	> 10 μM Compound: Mitomycin C	Antiproliferative activity against human CaSki cells after 48 hrs by MTT assay Antiproliferative activity against human CaSki cells after 48 hrs by MTT assay	[PMID: 29280632]
CCRF S-180	ED₅₀	4.4 μg/mL Compound: 30	Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days	[PMID: 19540628]
CHO-AA8	IC₅₀	1.08 nM Compound: Mitomycin C	Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours) Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)	[PMID: 2909741]
CHO-K1	IC₅₀	13.1 μg/mL Compound: Mitomycin C	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31195172]
CHO-K1	IC₅₀	13.2 μM Compound: Mitomycin c	Cytotoxicity against CHOK1 cells incubated for 24 hrs by MTT asasy Cytotoxicity against CHOK1 cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
CHO-K1	IC₅₀	39.8 μM Compound: Mitomycin C	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31858800]
CNE-2	IC₅₀	> 10 μM Compound: Mitomycin C	Antiproliferative activity against human CNE2 cells after 48 hrs by MTT assay Antiproliferative activity against human CNE2 cells after 48 hrs by MTT assay	[PMID: 29280632]
Daoy	IC₅₀	0.05 μg/mL Compound: Mitomycin	Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay	[PMID: 22014827]
Daoy	ED₅₀	0.08 μg/mL Compound: Mitomycin-C	Antiproliferative activity against human DaOY cells after 6 days by MTT assay Antiproliferative activity against human DaOY cells after 6 days by MTT assay	[PMID: 22672798]
Daoy	ED₅₀	0.1 μg/mL Compound: mitomycin C	Cytotoxicity against human DaOY cells after 3 days by MTT assay Cytotoxicity against human DaOY cells after 3 days by MTT assay	[PMID: 21115251]
Daoy	ED₅₀	0.14 μg/mL Compound: Mitomycin C	Cytotoxicity against human DaOY cells by MTT assay Cytotoxicity against human DaOY cells by MTT assay	[PMID: 20144547]
Daoy	ED₅₀	0.21 μM Compound: mitomycin C	Cytotoxicity against human Daoy cells by MTT assay Cytotoxicity against human Daoy cells by MTT assay	[PMID: 19061391]
Daudi	IC₅₀	0.45 μM Compound: Mitomycin C	Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay	[PMID: 20117936]
DLD-1	ED₅₀	0.1 μg/mL Compound: mitomycin	Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining	[PMID: 16309320]
DU-145	IC₅₀	0.17 μM Compound: MMC, NSC-26980	Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay	[PMID: 22522008]
DU-145	IC₅₀	0.17 μM Compound: MMC	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 20605274]
DU-145	IC₅₀	1.8 μM Compound: Mitomycin C	Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay	10.1007/s00044-010-9500-5
EL4	IC₅₀	0.06 μM Compound: Mitomycin	Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 27010926]
EL4	IC₅₀	3.94 μg/mL Compound: (21) mitomycin	In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay	[PMID: 12620075]
EMT6	ED₅₀	0.001 μM Compound: mytomycin C	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.	[PMID: 7452674]
EMT6	ED₅₀	0.7 μM Compound: mytomycin C	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.	[PMID: 7452674]
Fibroblast	EC₅₀	0.93 μM Compound: mitomycin	Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
GES1	IC₅₀	21.12 μM Compound: Mitomycin C	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HCT-116	GI₅₀	0.2 μM Compound: Mitomycin	Growth inhibition of human HCT116 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human HCT116 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
HCT-116	IC₅₀	0.5 μM Compound: Mytomycine	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 23501113]
HCT-116	IC₅₀	0.55 μM Compound: Mitomycin C	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
HCT-116	IC₅₀	0.56 μM Compound: MMC; MCC	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33581556]
HCT-116	IC₅₀	11.03 μM Compound: Mitomycin C	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HCT-15	IC₅₀	0.07 μM Compound: Mitomycin C	In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
HCT-15	IC₅₀	0.5 μM Compound: Mitomycin	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 24910974]
HCT-8	IC₅₀	0.083 μM Compound: MMC	Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay	[PMID: 18845441]
HCT-8	IC₅₀	0.6 μM Compound: Mitomycin C	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 16038545]
HeLa	IC₅₀	0.01 μg/mL Compound: Mytomycin C	Cytotoxicity against human HeLa cells after 3 days by methylene blue assay Cytotoxicity against human HeLa cells after 3 days by methylene blue assay	[PMID: 9644081]
HeLa	IC₅₀	0.06 μg/mL Compound: Mitomycin	Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay	[PMID: 22014827]
HeLa	ED₅₀	0.13 μg/mL Compound: Mitomycin-C	Antiproliferative activity against human HeLa cells after 6 days by MTT assay Antiproliferative activity against human HeLa cells after 6 days by MTT assay	[PMID: 22672798]
HeLa	ED₅₀	0.2 μg/mL Compound: mitomycin C	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 21115251]
HeLa	IC₅₀	0.2 μM Compound: MMC; MCC	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33581556]
HeLa	IC₅₀	0.27 μM Compound: MMC, NSC-26980	Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay	[PMID: 22522008]
HeLa	IC₅₀	0.27 μM Compound: MMC	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20605274]
HeLa	IC₅₀	1.13 μM Compound: MMC	Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HeLa	IC₅₀	1870 nM Compound: MC	Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
HeLa	IC₅₀	2 μM Compound: Mitomycin-C	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 25176329]
HeLa	IC₅₀	2 μM Compound: Mitomycin-c	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 24056146]
HeLa	IC₅₀	3 μM Compound: Mitomycin	Cytotoxicity against human HeLa cells after 48 hrs by SRB method Cytotoxicity against human HeLa cells after 48 hrs by SRB method	[PMID: 24913558]
HeLa	IC₅₀	3.3 μM Compound: mitomycin	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 19432411]
HeLa	IC₅₀	3.4 μM Compound: mitomycin C	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 22642381]
HeLa	IC₅₀	68 nM Compound: mitomycin C	Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay	[PMID: 11975488]
HeLa S3	IC₅₀	0.52 μM Compound: Mitomycin C	Cytotoxicity against human HeLa S3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa S3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35766102]
Hep 3B2	IC₅₀	0.01 μg/mL Compound: Mytomycin C	Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay	[PMID: 9644081]
HEp-2	ED₅₀	0.07 μg/mL Compound: Mitomycin C	Cytotoxicity against human Hep2 cells by MTT assay Cytotoxicity against human Hep2 cells by MTT assay	[PMID: 20144547]
HEp-2	ED₅₀	0.1 μg/mL Compound: mitomycin C	Cytotoxicity against human Hep2 cells after 3 days by MTT assay Cytotoxicity against human Hep2 cells after 3 days by MTT assay	[PMID: 21115251]
HEp-2	ED₅₀	0.12 μg/mL Compound: Mitomycin-C	Antiproliferative activity against human Hep2 cells after 6 days by MTT assay Antiproliferative activity against human Hep2 cells after 6 days by MTT assay	[PMID: 22672798]
HEp-2	IC₅₀	1.5 μM Compound: Mto-C	Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19939522]
Hepatocyte	EC₅₀	1.46 μM Compound: mitomycin	Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
HepG2	IC₅₀	> 10 μM Compound: Mitomycin C	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29280632]
HepG2	IC₅₀	0.13 μM Compound: Mitomycin	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	[PMID: 34128674]
HepG2	IC₅₀	0.14 μg/mL Compound: Mitomycin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
HepG2	IC₅₀	2.27 μM Compound: Mitomycin C	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
HepG2	IC₅₀	2937 nM Compound: MC	Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
HepG2	IC₅₀	32.63 μM Compound: Mitomycin C	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HepG2	IC₅₀	5.4 μM Compound: Mitomycin	Cytotoxicity against human HepG2 by MTT assay Cytotoxicity against human HepG2 by MTT assay	[PMID: 20968296]
HL-60	IC₅₀	0.1 μM Compound: MMC	Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay	[PMID: 22537363]
HL-60	IC₅₀	0.19 μM Compound: MMC	Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HL-60	IC₅₀	1.5 μM Compound: Mitomycin	Cytotoxicity against human HL60 by MTT assay Cytotoxicity against human HL60 by MTT assay	[PMID: 20968296]
HL-60	IC₅₀	1.5 μM Compound: mitomycin	Cytotoxicity against human HL60 cells after 48 hrs by SRB assay Cytotoxicity against human HL60 cells after 48 hrs by SRB assay	[PMID: 19432411]
HL-60	IC₅₀	1.8 μM Compound: mitomycin C	Cytotoxicity against human HL60 cells after 48 hrs by SRB assay Cytotoxicity against human HL60 cells after 48 hrs by SRB assay	[PMID: 22642381]
HL-60	IC₅₀	3 μM Compound: Mitomycin	Cytotoxicity against human HL60 cells after 48 hrs by SRB method Cytotoxicity against human HL60 cells after 48 hrs by SRB method	[PMID: 24913558]
HL-60	IC₅₀	410 nM Compound: MC	Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
HT-1080	IC₅₀	0.15 μg/mL Compound: Mitomycin	Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
HT-29	IC₅₀	0.02 μg/mL Compound: (21) mitomycin	In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
HT-29	IC₅₀	0.06 μM Compound: Mitomycin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27010926]
HT-29	IC₅₀	0.44 μM Compound: Mitomycin C	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
HT-29	IC₅₀	0.9 μM Compound: mitomycin C	Cytotoxicity against human HT29 cells after 72 hrs by MTT assay Cytotoxicity against human HT29 cells after 72 hrs by MTT assay	[PMID: 18222567]
HT-29	IC₅₀	2.1 μM Compound: mitomycin C	Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol	[PMID: 18222567]
HT-29	IC₅₀	7.099 μM Compound: 1	Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay	[PMID: 28395199]
HT-29	IC₅₀	99 nM Compound: Mitomycin C	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
Huh-7	GI₅₀	2 μM Compound: Mitomycin	Growth inhibition of human HuH7 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human HuH7 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
HuT78	IC₅₀	66 nM Compound: MC	Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
Jurkat	IC₅₀	0.43 μM Compound: Mitomycin	Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 31490685]
Jurkat	IC₅₀	303 nM Compound: MC	Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay	[PMID: 26541587]
Jurkat	IC₅₀	578 nM Compound: MC	Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
K562	IC₅₀	0.47 μM Compound: Mitomycin C	Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay	[PMID: 20117936]
K562	IC₅₀	3.35 μg/mL Compound: Mitomycin	Antitumor activity against human K562 cell line by MTT assay Antitumor activity against human K562 cell line by MTT assay	[PMID: 16455245]
K562-Lucena 1	IC₅₀	2.75 μM Compound: Mitomycin C	Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay	[PMID: 20117936]
KB	IC₅₀	0.01 μg/mL Compound: mitomycin C	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 12502326]
KB	IC₅₀	0.01 μg/mL Compound: mitomycin C	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 11473432]
KB	IC₅₀	0.08 μg/mL Compound: Mitomycin	Cytotoxicity against human KB cells after 1 to 11 days by MTT assay Cytotoxicity against human KB cells after 1 to 11 days by MTT assay	[PMID: 22014827]
KB	ED₅₀	0.13 μg/mL Compound: mitomycin	Cytotoxicity against human KB cells after 3 days by methylene blue staining Cytotoxicity against human KB cells after 3 days by methylene blue staining	[PMID: 16309320]
KB	IC₅₀	0.4 μM Compound: Mytomycin C	In vitro cytotoxicity determined against human epidermoid carcinoma KB cells by MTT assay In vitro cytotoxicity determined against human epidermoid carcinoma KB cells by MTT assay	10.1016/S0960-894X(97)00100-5
KB	IC₅₀	0.4 μM Compound: Mitomycin C	In vitro antitumor activity against human epidermoid carcinoma KB cells by MTT assay. In vitro antitumor activity against human epidermoid carcinoma KB cells by MTT assay.	10.1016/0960-894X(95)00353-U
KB	ED₅₀	0.56 μg/mL Compound: Mitomycin	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 16643051]
KB	IC₅₀	0.6 μM Compound: Mitomycin C	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 16038545]
KB 3-1	IC₅₀	0.1 μg/mL Compound: Mitomycin C	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay	[PMID: 20149652]
L02	IC₅₀	25.023 μM Compound: 1	Cytotoxicity against human LO2 cells after 72 hrs by MTT assay Cytotoxicity against human LO2 cells after 72 hrs by MTT assay	[PMID: 28395199]
L1210	IC₅₀	0.6 μM Compound: Mytomycin C	In vitro cytotoxicity determined against murine leukemia L1210 cells by MTT assay In vitro cytotoxicity determined against murine leukemia L1210 cells by MTT assay	10.1016/S0960-894X(97)00100-5
L1210	IC₅₀	0.6 μM Compound: Mitomycin C	In vitro antitumor activity against murine lymphoma L1210 cells by MTT assay. In vitro antitumor activity against murine lymphoma L1210 cells by MTT assay.	10.1016/0960-894X(95)00353-U
L6	ED₅₀	20.7 μM Compound: mitomycin C	Cytotoxicity against human SCL6 cells by MTT assay Cytotoxicity against human SCL6 cells by MTT assay	[PMID: 12880314]
M14	IC₅₀	0.47 μM Compound: Mitomycin C	Cytotoxicity against human M14 cells after 72 hrs by MTS assay Cytotoxicity against human M14 cells after 72 hrs by MTS assay	[PMID: 26335269]
MCF7	IC₅₀	0.06 μM Compound: Mitomycin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 27010926]
MCF7	ED₅₀	0.09 μg/mL Compound: Mitomycin-C	Antiproliferative activity against human MCF7 cells after 6 days by MTT assay Antiproliferative activity against human MCF7 cells after 6 days by MTT assay	[PMID: 22672798]
MCF7	ED₅₀	0.1 μg/mL Compound: mitomycin C	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 21115251]
MCF7	ED₅₀	0.14 μg/mL Compound: Mitomycin C	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 20144547]
MCF7	IC₅₀	0.2 μM Compound: mitomycin C	Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay	[PMID: 18752870]
MCF7	IC₅₀	0.2 μM Compound: MMC, mitomycin c	Cytotoxicity against human MCF7 cells by Alamar blue assay Cytotoxicity against human MCF7 cells by Alamar blue assay	[PMID: 18037301]
MCF7	IC₅₀	0.2 μM Compound: Mitomycin-C	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 25259515]
MCF7	IC₅₀	0.93 μg/mL Compound: (21) mitomycin	In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay	[PMID: 12620075]
MCF7	EC₅₀	0.96 μM Compound: mitomycin	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
MCF7	EC₅₀	0.96 μM Compound: Mitomycin	Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method	[PMID: 17950604]
MCF7	IC₅₀	1.2 μM Compound: MMC, mitomycin c	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 18037301]
MCF7	IC₅₀	1.5 μM Compound: Mitomycin C	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 16038545]
MCF7	IC₅₀	1.8 μM Compound: Mitomycin C	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35766102]
MCF7	IC₅₀	16.71 μM Compound: Mitomycin C	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
MCF7	GI₅₀	2.5 μM Compound: Mitomycin	Growth inhibition of human MCF7 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human MCF7 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
MCF7	IC₅₀	5 μM Compound: MMC, mitomycin c	Cytotoxicity against human MCF7 cells after 24 hrs Cytotoxicity against human MCF7 cells after 24 hrs	[PMID: 18037301]
MDA-MB-231	EC₅₀	0.103 μM Compound: Mitomycin	Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days	[PMID: 24436995]
MDA-MB-231	EC₅₀	1.25 μM Compound: Mitomycin	Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days	[PMID: 24436995]
MDA-MB-231	IC₅₀	2.89 μM Compound: Mitomycin C	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
MDA-MB-231	IC₅₀	4.4 μM Compound: Mitomycin C	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29280632]
MDA-MB-468	IC₅₀	0.27 μM Compound: Mitomycin C	In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
MDA-MB-468	IC₅₀	0.5 μM Compound: Mitomycin C	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay	[PMID: 26335269]
MKN-74	GI₅₀	1.7 μM Compound: Mitomycin	Growth inhibition of human MKN74 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human MKN74 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
NCI-H226	IC₅₀	0.58 μM Compound: Mitomycin C	Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay	[PMID: 26335269]
NCI-H23	IC₅₀	2 μM Compound: Mytomycin	Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay	[PMID: 23792352]
NCI-H596	IC₅₀	11.969 μM Compound: 1	Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay	[PMID: 28395199]
NIH3T3	IC₅₀	1.7 μM Compound: 1, Mitomycin C (MMC)	Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay	[PMID: 11855992]
NUGC-4	ED₅₀	19.1 μM Compound: mitomycin C	Cytotoxicity against human NUGC4 cells by MTT assay Cytotoxicity against human NUGC4 cells by MTT assay	[PMID: 12880314]
P388	IC₅₀	0.02 μg/mL Compound: mitomycin C	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 8254344]
P388	IC₅₀	0.06 μM Compound: Mitomycin	Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 27010926]
P388	IC₅₀	0.15 μg/mL Compound: Mitomycin C	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 17576066]
P388	IC₅₀	1.5 μg/mL Compound: (21) mitomycin	In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay	[PMID: 12620075]
P388	IC₅₀	3000 nM Compound: Mitomycin C	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	4.03 μM Compound: Mitomycin C	Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay	[PMID: 20117936]
PC-3	EC₅₀	0.14 μM Compound: mitomycin	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
PC-3	EC₅₀	0.14 μM Compound: Mitomycin	Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method	[PMID: 17950604]
PC-3	IC₅₀	0.2 μM Compound: Mitomycin-C	Cytotoxicity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay	10.1039/C5MD00289C
PC-3	IC₅₀	1.4 μM Compound: Mitomycin	Cytotoxicity against human PC3 cells after 72 hrs by CCK-8 assay Cytotoxicity against human PC3 cells after 72 hrs by CCK-8 assay	[PMID: 26615890]
PC-3	IC₅₀	1.4 μM Compound: Mitomycin C	Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay	10.1007/s00044-010-9500-5
PC-3	IC₅₀	1.5 μM Compound: Mitomycin-C	Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay	10.1007/s00044-012-0424-0
PC-3	IC₅₀	1.5 μM Compound: Mitomycin-C	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 25176329]
PC-3	IC₅₀	1.5 μM Compound: Mitomycin-c	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 24056146]
PC-3	IC₅₀	1.5 μM Compound: Mitomycin-C	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay	10.1039/C3MD00055A
PC-3	IC₅₀	1.5 μM Compound: Mto-C	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19939522]
RKO	IC₅₀	1.75 μg/mL Compound: Mitomycin	Antitumor activity against human RKO cell line by MTT assay Antitumor activity against human RKO cell line by MTT assay	[PMID: 16455245]
SF-295	IC₅₀	0.54 μM Compound: Mitomycin C	Cytotoxicity against human SF295 cells after 72 hrs by MTS assay Cytotoxicity against human SF295 cells after 72 hrs by MTS assay	[PMID: 26335269]
SF-539	IC₅₀	3.8 x 10^-2 μM Compound: Mitomycin C	Cytotoxicity against human SF539 cells after 72 hrs by MTS assay Cytotoxicity against human SF539 cells after 72 hrs by MTS assay	[PMID: 26335269]
Sf9	IC₅₀	3 μg/mL Compound: mitomycin C	Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay	[PMID: 11277765]
SGC-7901	IC₅₀	2.05 μM Compound: Mitomycin C	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 23999045]
SK-BR-3	IC₅₀	1 μM Compound: Mitomycin	Cytotoxicity against human SKBR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 31490685]
SK-OV-3	GI₅₀	0.1 μM Compound: Mitomycin	Growth inhibition of human SKOV3 cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human SKOV3 cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
SK-OV-3	IC₅₀	0.18 μM Compound: Mitomycin C	In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
SMMC-7721	IC₅₀	2.44 μg/mL Compound: Mitomycin	Antitumor activity against human SMMC7721 cell line by MTT assay Antitumor activity against human SMMC7721 cell line by MTT assay	[PMID: 16455245]
SMMC-7721	IC₅₀	5.4 μM Compound: mitomycin	Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay	[PMID: 19432411]
SMMC-7721	IC₅₀	5.6 μM Compound: mitomycin C	Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay	[PMID: 22642381]
SW480	IC₅₀	0.79 μM Compound: Mitomycin C	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
T47D	IC₅₀	0.4 μM Compound: Mitomycin C	In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
T47D	IC₅₀	16970 nM Compound: MC	Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay	[PMID: 26541587]
THP-1	IC₅₀	0.1 μM Compound: Mitomycin-C	Cytotoxicity against human THP1 cells after 48 hrs by SRB assay Cytotoxicity against human THP1 cells after 48 hrs by SRB assay	[PMID: 25259515]
THP-1	IC₅₀	0.5 μM Compound: Mitomycin-C	Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay	10.1039/C5MD00289C
THP-1	IC₅₀	1.5 μM Compound: Mitomycin-C	Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay	10.1007/s00044-012-0424-0
THP-1	IC₅₀	1.5 μM Compound: Mitomycin-C	Cytotoxicity against human THP1 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay Cytotoxicity against human THP1 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay	10.1039/C3MD00055A
U2OS	IC₅₀	8.45 μM Compound: Mitomycin C	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34847663]
U-87MG ATCC	GI₅₀	1.8 μM Compound: Mitomycin	Growth inhibition of human U87MG cells after 72 hrs by Cell-Titer Glo assay Growth inhibition of human U87MG cells after 72 hrs by Cell-Titer Glo assay	[PMID: 28682609]
WiDr	ED₅₀	0.15 μg/mL Compound: Mitomycin C	Cytotoxicity against human WiDr cells by MTT assay Cytotoxicity against human WiDr cells by MTT assay	[PMID: 20144547]
WiDr	ED₅₀	0.18 μM Compound: mitomycin C	Cytotoxicity against human WiDr cells by MTT assay Cytotoxicity against human WiDr cells by MTT assay	[PMID: 19061391]
WiDr	ED₅₀	0.35 μg/mL Compound: Mitomycin	Cytotoxicity against human WiDr cells after 72 hrs Cytotoxicity against human WiDr cells after 72 hrs	[PMID: 16643051]

体外研究
(In Vitro)

HCT116 (p53^-/-) 细胞对丝裂霉素 C (Ametycine) 或单独的 TRAIL 的敏感性最低。然而，令人惊讶的是，MMC 和 TRAIL 的联合处理显著降低了细胞活力。尽管单独使用丝裂霉素 C 和 TRAIL 的效果适中，但丝裂霉素 C 大大增强了 TRAIL 对抑制细胞增殖的作用。单独使用丝裂霉素 C 和 TRAIL 处理分别诱导 9.5% 和 35.0% 的细胞凋亡。然而，丝裂霉素 C 和 TRAIL 联合处理可将细胞凋亡率提高至 66.6%^[1]。
丝裂霉素 C 是一种细胞毒性化疗剂，也会以 DNA 交联的形式引起 DNA 损伤作为多种 DNA 单加合物，已知可诱导 p53^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

携带异种移植 HCT116 (p53^-/-) 结肠肿瘤和 HT-29 结肠肿瘤的小鼠每隔一段时间用丝裂霉素 C (阿米霉素；ip，1 mg/kg) 和 TRAIL (iv，100 μg) 处理天。用联合处理方案的 10 个连续周期处理动物。联合疗法显著抑制了肿瘤生长，并且不影响小鼠的体重，表明丝裂霉素 C 和 TRAIL 的处理组合具有良好的耐受性，并且在体内具有抗肿瘤活性^[1]。
膀胱内 Mitomycin C 滴注对体重有影响。在连续 3 次每周滴注 1 mg/mL 丝裂霉素 C 后，体重几乎没有增加，而与 MMC 处理的大鼠相比，其他 3 组大鼠的体重增加有统计学意义^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

334.33

Formula

C₁₅H₁₈N₄O₅

CAS 号

50-07-7

性状

固体

颜色

Blue to black

中文名称

丝裂霉素 C；丝裂霉素；密吐霉素；自力霉素；嘧吡霉素；突变霉素

结构分类

初始来源

微生物

Streptomyces

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (149.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9911 mL	14.9553 mL	29.9106 mL
5 mM	0.5982 mL	2.9911 mL	5.9821 mL
10 mM	0.2991 mL	1.4955 mL	2.9911 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.22 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.22 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.98%

选择批次：

Data Sheet (655 KB) SDS (644 KB)

COA (202 KB) HNMR (268 KB) RP-HPLC (204 KB) LCMS (98 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Cheng H, et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 2012 Sep 1;11(17): 3312-23. [Content Brief]

[2]. Abbas T, et al. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25;277(43):40513-9. [Content Brief]

[3]. Michielsen D, et al. Mitomycin C: functional bladder damage in rats after repeat intravesical instillations. J Urol. 2005 Jun;173(6):2166-70. [Content Brief]

Cell Assay ^[1]	Colon adenocarcinoma HCT116 and HT-29 human colon cancer cells are used. The CellTiter-Glo Luminescent Cell Viability Assay is used to measure cell viability, which use a unique, stable form of luciferase to measure ATP as an indicator of viable cells, and the luminescent signal produced is proportional to the number of viable cells present in culture. Cells are pretreated with Mitomycin C (5 μM) for 12 h or 24 h, and then exposed to different concentrations of TRAIL for 12 h. An equal volume (100 μL) of CellTiter-Glo^TM reagent is added and the solution is mixed gently for 2 min on an orbital shaker. Mixture is incubated at room temperature for 10 min to allow luminescent signal to stabilize, and then imaging is performed using the Xenogen IVIS system to quantify the cell viability^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]^[3]	Mice^[1] Four- to 6-wk-old NCr nude mice are treated with Mitomycin C (1 mg/kg) by intraperitoneal injection for 24 h, followed by one intravenous dose of purified rhTRAIL (100 μg). As a negative control, a subset of the mice are injected (i.p. and i.v.) with saline (vehicle) at the same frequency of treatment. Animals are treated for 3 consecutive weeks. The tumor size is monitored every week using caliper measurements of the tumor volume. Rats^[3] Young adult female Wistar rats at age 13 weeks with a median weight of 217 g (range 187 to 255) are randomized into 4 groups of 10 each, namely a normal group with no instillations, an NaCl 0.9% or placebo group that received instillations with the solvent of the chemotherapeutic agent, Mitomycin C (1 mg/mL) group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Cheng H, et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 2012 Sep 1;11(17): 3312-23. [Content Brief] [2]. Abbas T, et al. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25;277(43):40513-9. [Content Brief] [3]. Michielsen D, et al. Mitomycin C: functional bladder damage in rats after repeat intravesical instillations. J Urol. 2005 Jun;173(6):2166-70. [Content Brief]

Mitomycin C 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9911 mL	14.9553 mL	29.9106 mL	74.7764 mL
	5 mM	0.5982 mL	2.9911 mL	5.9821 mL	14.9553 mL
	10 mM	0.2991 mL	1.4955 mL	2.9911 mL	7.4776 mL
	15 mM	0.1994 mL	0.9970 mL	1.9940 mL	4.9851 mL
	20 mM	0.1496 mL	0.7478 mL	1.4955 mL	3.7388 mL
	25 mM	0.1196 mL	0.5982 mL	1.1964 mL	2.9911 mL
	30 mM	0.0997 mL	0.4985 mL	0.9970 mL	2.4925 mL
	40 mM	0.0748 mL	0.3739 mL	0.7478 mL	1.8694 mL
	50 mM	0.0598 mL	0.2991 mL	0.5982 mL	1.4955 mL
	60 mM	0.0499 mL	0.2493 mL	0.4985 mL	1.2463 mL
	80 mM	0.0374 mL	0.1869 mL	0.3739 mL	0.9347 mL
	100 mM	0.0299 mL	0.1496 mL	0.2991 mL	0.7478 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Mitomycin C (Synonyms: 丝裂霉素 C ; Ametycine)

Customer Review

MCE 顾客使用本产品发表的 113 篇科研文献

Mitomycin C 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Mitomycin C 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Mitomycin C (Synonyms: 丝裂霉素 C ; Ametycine)

Customer Review

Mitomycin C 相关抗体

MCE 顾客使用本产品发表的 113 篇科研文献

Mitomycin C 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Mitomycin C 相关抗体:

摩尔计算器

稀释计算器

Mitomycin C 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z